Company Analysis
Sign in

Biogen Inc. (BIIB)

Nasdaq: BIIB · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.9
◀ Past 6.4● Present 6.7▶ Future 4.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

606 patents granted to the 20 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Biogen Inc.’s names, not what it holds today.

Patents granted
606
596 utility, 7 design, 3 reissue, 1976 to Dec 31, 2025
Granted in 2025
22
Against 22 in 2024 and 26 in 2023
Applications published
760
35 of them in 2025
Names they are printed under
20
a subsidiary, its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals64
Organic fine chemistry28
Medical technology19
Biotechnology18
Analysis of biological materials9
Measurement3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name20 counted
Biogen MA Inc. a subsidiary
US, as the owner printed on each patent. 20 more under the same name are not counted (printed in GB)
250 granted
160 published
Biogen MA Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
273 published
Biogen Inc. its own name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in LI, printed in GB)
136 granted
21 published
REATA PHARMACEUTICALS HOLDINGS, LLC a subsidiary
US, as the owner printed on each patent
68 granted
58 published
Biogen Idec Inc. a former name
US, as the owner printed on each patent
46 granted
74 published
IDEC Pharmaceuticals Corporation a former name
US, as the owner printed on each patent
40 granted
37 published
Convergence Pharmaceuticals Limited a subsidiary
GB, as the owner printed on each patent
24 granted
10 published
Conforma Therapeutics Corporation a subsidiary
US, as the owner printed on each patent
10 granted
23 published
BIOGEN CHESAPEAKE LLC a subsidiary
US, as the owner printed on each patent. 4 more under the same name are not counted (printed in GB)
13 granted
13 published
Biogen International Neuroscience GmbH a subsidiary
CH, as the owner printed on each patent
12 granted
14 published
Biogen Inc. its own name
named as the applicant on its applications, in US
0 granted
17 published
Convergence Pharmaceuticals Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
17 published
REATA PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
13 published
NightstaRx Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
9 published
ALCYONE THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
7 granted
0 published
BIOGEN CHESAPEAKE LLC a subsidiary
named as the applicant on its applications, in US
0 granted
6 published
Biogen International Neuroscience GmbH a subsidiary
named as the applicant on its applications, in CH
0 granted
6 published
ALCYONE THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
Biogen Idec Inc. a former name
named as the applicant on its applications, in US
0 granted
3 published
REATA PHARMACEUTICALS HOLDINGS, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Names not counted (2)
BIOGEN INC.
No country is printed for it. 0 granted and 12 published under it are not counted.
BIOGEN INC.
Most of its patents print NL; this name counts in US. 8 granted and 0 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,289Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereofPharmaceuticalsBiogen MA Inc.
Nov 18, 202512,472,171Methods for treating hypercholesterolemiaPharmaceuticalsBiogen MA Inc.
Nov 11, 202512,467,929Methods of detecting UBE3A proteinMeasurementBiogen MA Inc.
Oct 14, 202512,441,980Methods for overcoming glutamine deprivation during mammalian cell cultureBiotechnologyBiogen MA Inc.
Sep 30, 202512,429,487Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosisBiotechnologyBiogen MA Inc.
Sep 23, 202512,421,224Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitorsOrganic fine chemistryBiogen MA Inc.
Sep 2, 202512,404,263ASK1 inhibiting agentsPharmaceuticalsBiogen MA Inc.
Aug 19, 202512,392,784Method of assessing risk of PMLBiotechnologyBiogen MA Inc.
Aug 19, 202512,391,697Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinasePharmaceuticalsBiogen MA Inc.
Aug 12, 202512,385,925Anti-VLA-4 related assaysAnalysis of biological materialsBiogen MA Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387400TYK2 INHIBITORSPharmaceuticalsBiogen MA Inc.
Dec 18, 20252025/0382568USE OF PERFUSION SEED CULTURES TO IMPROVE BIOPHARMACEUTICAL FEDBATCH PRODUCTION CAPACITY AND PRODUCT QUALITYBiotechnologyBiogen MA Inc.
Nov 27, 20252025/0361263C17 POLAR-SUBSTITUTED HETEROAROMATIC SYNTHETIC TRITERPENOIDS AND METHODS OF USE THEREOFPharmaceuticalsREATA PHARMACEUTICALS HOLDINGS, LLC
Nov 20, 20252025/0353841HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASEPharmaceuticalsBiogen MA Inc.
Nov 20, 20252025/0353813ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17PharmaceuticalsREATA PHARMACEUTICALS HOLDINGS, LLC
Nov 20, 20252025/0352721IMPLANTABLE INTRAVENTRICULAR SAMPLING AND INFUSION ACCESS DEVICEMedical technologyBiogen MA Inc.
Oct 16, 20252025/0320493METHODS FOR REDUCING TAU EXPRESSIONBiotechnologyBiogen MA Inc.
Oct 9, 20252025/0313563GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOFPharmaceuticalsBiogen MA Inc.
Oct 2, 20252025/0304700ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOFPharmaceuticalsBiogen MA Inc.
Oct 2, 20252025/0304586CRYSTALLINE POLYMORPHS OF N-METHYL-N-((1S,3S)-3-METHYL-3-((6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL)OXY)CYCLOBUTYL)ACRYLAMIDEPharmaceuticalsBiogen MA Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 51 · Organic fine chemistry 11 · Biotechnology 8 · Medical technology 4 · Analysis of biological materials 1 · Chemical engineering 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BIIB · research, not advice